Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADXS11-001 with Chemoradiation for Anal Cancer
NCT01671488Phase 2Terminated
- Sponsor
- Brown University
- Start
- Feb 2013
- Primary completion
- Feb 2018
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axalimogene filolisbac in anal cancer, sponsored by Brown University. Primary endpoints: Safety of ADXS11-001 with Chemoradiation and 6-month Clinical Complete Response Rate. Started Feb 2013; status: terminated.
02
Drugs
axalimogene filolisbac
03
Conditions
anal cancer
Beyond the preview
Go deeper on NCT01671488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01671488.